Regulation (EU) No 1227/2011 of the European Parliament and of the Council of 25 October 2011 on wholesale energy market integrity and transparency Text with EEA relevance

OJ L 326, 8.12.2011, p. 1–16 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
This document has been published in a special edition(s) (HR)

OJ L 326, 8.12.2011, p. 1–16

Judgment of the Court (Ninth Chamber) of 15 April 2021.
Italmobiliare SpA and Others v European Commission.
Case C-694/19 P.

ECLI identifier: ECLI:EU:C:2021:286

Judgment of the Court (Fourth Chamber) of 25 March 2021.
Xellia Pharmaceuticals ApS and Alpharma, LLC, anciennement Zoetis Products LLC v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine – Rights of the defence – Reasonable time – Loss of documents due to the passage of time – General duty of care – Regulation (EC) No 1/2003 – Second subparagraph of Article 23(2) – Maximum amount of the fine – Taking into account the business year preceding that in which the European Commission’s decision was adopted – Last full year of normal economic activity.
Case C-611/16 P.

Digital reports (Court Reports - general - 'Information on unpublished decisions' section)

Digital reports

ECLI identifier: ECLI:EU:C:2021:245

Judgment of the Court (Fourth Chamber) of 25 March 2021.
H. Lundbeck A/S and Lundbeck Ltd v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine – Sales directly or indirectly related to the infringement.
Case C-591/16 P.

Digital reports (Court Reports - general - 'Information on unpublished decisions' section)

Digital reports

ECLI identifier: ECLI:EU:C:2021:243

Judgment of the Court (Fourth Chamber) of 25 March 2021.
Arrow Group ApS and Arrow Generics Ltd v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.
Case C-601/16 P.

ECLI identifier: ECLI:EU:C:2021:244

Judgment of the Court (Fourth Chamber) of 25 March 2021.
Merck KGaA v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.
Case C-614/16 P.

ECLI identifier: ECLI:EU:C:2021:246

Judgment of the Court (Fourth Chamber) of 25 March 2021.
Generics (UK) Ltd v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressants (citalopram) – Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.
Case C-588/16 P.

ECLI identifier: ECLI:EU:C:2021:242

Judgment of the Court (Fourth Chamber) of 25 March 2021.
Sun Pharmaceutical Industries Ltd, anciennement Ranbaxy Laboratories Ltd and Ranbaxy (UK) Ltd v European Commission.
Appeal – Competition – Agreements, decisions and concerted practices – Pharmaceutical products – Market for antidepressant medicines (citalopram) – Settlement agreements concerning process patents concluded between a manufacturer of originator medicines holding those patents and manufacturers of generic medicines – Article 101 TFEU – Potential competition – Restriction by object – Characterisation – Calculation of the amount of the fine.
Case C-586/16 P.

ECLI identifier: ECLI:EU:C:2021:241

Order of the Court (Sixth Chamber) of 16 March 2021.
Criminal proceedings against DS.
Request for a preliminary ruling from the Tribunal correctionnel de Limoges.
Case C-557/20.

ECLI identifier: ECLI:EU:C:2021:204

Judgment of the Court (Fourth Chamber) of 18 March 2021.
Pometon SpA v European Commission.
Appeal – Agreements, decisions and concerted practices – European steel abrasives market – Participation in bilateral and multilateral contacts with the aim of coordinating prices throughout the European Economic Area (EEA) – ‘Hybrid’ procedure having led successively to the adoption of a settlement decision and a decision made under the ordinary procedure – Charter of Fundamental Rights of the European Union – Article 41 – Principle of impartiality of the European Commission – Article 48 – Presumption of innocence – Obligation to state reasons – Single and continuous infringement – Duration of the infringement – Equal treatment – Unlimited jurisdiction.
Case C-440/19 P.

ECLI identifier: ECLI:EU:C:2021:214